Segra International is excited to introduce a new breeder partnership with Purple City Genetics, bringing a curated selection of genetics to licensed cultivators in Canada and regulated international medical markets. This launch represents an important step in expanding access to breeder-led cultivars through verified cannabis tissue culture and structured clone programs designed specifically for professional operators.

Purple City Genetics has earned recognition within the North American cultivation community for thoughtful breeding, careful selection practices, and a focus on modern hybrid development. Their work emphasizes structural integrity, balanced vigor, and expressive aromatic profiles. For commercial cultivation teams, these characteristics support predictable flowering windows, manageable plant architecture, and consistent performance across production cycles.

Segra’s first release of Purple City Genetics cultivars will include Forbidden Blueprints, Futura Haze, G Runtz, Gush Mints 1:1, Lemon Sportif, Marmalade, and The Bridge. Together, these cultivars offer a diverse mix of hybrid expressions suitable for premium flower programs and extraction-focused operations. The selection reflects a combination of market interest and cultivation practicality, giving operators options that align with both branding and production objectives.

A key element of this launch is the delivery format. These genetics will be introduced through Segra’s cannabis tissue culture platform, along with scalable cannabis clone programs and select Autoflower and Photoperiod seed offerings where permitted. Tissue culture supports uniform crop starts, structured propagation planning, and controlled onboarding into existing facilities. For regulated operators, this format also supports documentation, traceability, and biosecurity alignment.

Segra’s approach integrates genetic identity assurance through DNA fingerprinting and molecular pathogen screening, including testing for risks such as Hop Latent Viroid (HLVd). This verification helps confirm cultivar identity while supporting plant health at the earliest stages of production. For international medical markets, where documentation and supply chain clarity are especially important, this structured process strengthens overall confidence in genetic continuity.

The introduction of Purple City Genetics through Segra is more than a cultivar release. It reflects a shared commitment to pairing respected breeding programs with verified propagation systems suited for licensed environments. As Canadian and international medical markets continue to evolve, access to well-documented, performance-focused genetics will remain a priority for professional cultivation teams.

Operators interested in learning more about the Purple City Genetics release can explore detailed cultivar specifications in the Segra catalogue. To discuss onboarding or deployment planning, the Segra team is available to connect directly. New licensed customers are encouraged to register to access availability and program information.

Download the Seed Catalogue at https://segra-intl.com/purple-city-genetics

Explore the Purple City Genetics plant selection in our catalogue.

Connect with the team at https://www.segra-intl.com/get-in-touch  

Register as a licensed customer at https://www.segra-intl.com/signup